We are the leading French company in the animal health sector, and we are headquartered in Libourne, France.
With more than 7,000 employees located in 47 countries, Ceva strives daily to bring to life its vision as a One Health company: “Together, beyond animal health”. Our 21 R&D centers and 33 production sites worldwide attest to our commitment to research and the development of increasingly innovative solutions.
Our “Together, Beyond Animal Health” vision emphasizes that the health and wellbeing of people, animals and our planet are totally interlinked.
We innovate to help pet owners live in harmony with their four-legged companions. Ceva invests in behaviour, cardiology & nephrology, dermatology & antibiotherapy product R&D, along with educational programmes to raise awareness among professionals and pet owners.
Ceva has been a leader in poultry vaccination for over 20 years, striving to develop safe, effective and innovative vaccines for all players in the poultry value chain. Our services ensure optimal vaccine implementation, an in-depth understanding of bird health, and stakeholder training.
Ceva is committed to preventive medicine, focusing on vaccine research and development, providing treatments and support services to prevent diseases, maintain animal quality of life, and ensure human health.
Ceva actively contributes to sustainable development in the industry, offering tailor-made solutions for the health and protection of animals from birth throughout their lives. Our thirst for innovation has led to unique solutions, like the vaccine against Q fever, a zoonotic disease affecting ruminants.
In 1999, two French pharmaceutical companies, Sanofi and Synthélabo, merged to form Sanofi-Synthélabo. Soon afterwards the new company divested its animal health and nutrition business. This business was acquired through a leveraged management buyout. This resulted in the establishment of Ceva Santé Animale with its headquarters in Libourne, near Bordeaux.
In 2007, Ceva management and employees, many of them qualified and experienced veterinarians, became majority shareholders in the company’s third financing round.
Ceva inherited a rich history of vaccine development and manufacturing through its European subsidiary, Ceva Phylaxia. Founded in Hungary in 1912, the Phylaxia Vaccine Production Cie produced the first vaccine against classical swine fever. World famous scientists including József Marek and Aladár Aujeszky were closely associated with the company.
Over time we have become a truly global research-based business and a recognised leader and pioneer in areas as diverse as hatchery vaccination, reproductive management of farm animals and behavioural control products for dogs and cats.
This growth has been achieved both organically and through carefully chosen strategic acquisitions of companies from all around the world.
Since 1999, we have become the world’s fifth largest animal health company, and became the leading French animal health company.